These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 25686120)
41. Tyrosine kinases as targets for cancer therapy. Krause DS; Van Etten RA N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887 [No Abstract] [Full Text] [Related]
42. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Faivre S; Djelloul S; Raymond E Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796 [TBL] [Abstract][Full Text] [Related]
43. Targeting PRL phosphatases in hematological malignancies. Xiao S; Chen H; Bai Y; Zhang ZY; Liu Y Expert Opin Ther Targets; 2024 Apr; 28(4):259-271. PubMed ID: 38653737 [TBL] [Abstract][Full Text] [Related]
44. Role of tyrosine kinase inhibitors in cancer therapy. Arora A; Scholar EM J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463 [TBL] [Abstract][Full Text] [Related]
45. Targeting receptor tyrosine kinases in solid tumors. Zhang J; Hochwald SN Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395 [TBL] [Abstract][Full Text] [Related]
46. [Epigenetic therapy for hematologic malignancies]. Kobayashi Y Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440 [TBL] [Abstract][Full Text] [Related]
48. Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition. Tinsley S; Meja K; Shepherd C; Khwaja A Br J Haematol; 2015 Jul; 170(2):275-8. PubMed ID: 25640480 [No Abstract] [Full Text] [Related]
49. Protein phosphorylation on tyrosine in bacteria. Cozzone AJ; Grangeasse C; Doublet P; Duclos B Arch Microbiol; 2004 Mar; 181(3):171-81. PubMed ID: 14745484 [TBL] [Abstract][Full Text] [Related]
51. Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: evidence from vascular-targeted transgenic mice of AT2 receptor. Matsubara H; Shibasaki Y; Okigaki M; Mori Y; Masaki H; Kosaki A; Tsutsumi Y; Uchiyama Y; Fujiyama S; Nose A; Iba O; Tateishi E; Hasegawa T; Horiuchi M; Nahmias C; Iwasaka T Biochem Biophys Res Commun; 2001 Apr; 282(5):1085-91. PubMed ID: 11302725 [TBL] [Abstract][Full Text] [Related]
52. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Wu H; Medeiros LJ; Young KH Blood Rev; 2018 Jan; 32(1):8-28. PubMed ID: 28802908 [TBL] [Abstract][Full Text] [Related]
53. The cancer stem cell gamble. Kaiser J Science; 2015 Jan; 347(6219):226-9. PubMed ID: 25593170 [No Abstract] [Full Text] [Related]
54. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals]. Grimm CF; Blum HE; Geissler M Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620 [No Abstract] [Full Text] [Related]
55. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Yang K; Fu LW Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000 [TBL] [Abstract][Full Text] [Related]